Form 4: Upstream Bio Director Erez Chimovits Granted Stock Options with OrbiMed Transfer Obligation

Upstream Bio, Inc. Director and 10% Owner Erez Chimovits was granted 17,096 stock options with a $11.59 exercise price, subject to vesting and an obligation to transfer benefits to OrbiMed entities.

Summary

• Erez Chimovits, a Director and 10% Owner of Upstream Bio, Inc. (UPB), was granted 17,096 stock options.
• The options have an exercise price of $11.59 per share.
• The transaction date for the option grant was June 10, 2025.
• The options will vest upon the earlier of June 10, 2026, or the date of the next Annual Meeting of Stockholders, contingent on Mr. Chimovits' continued service.
• The options expire on June 9, 2035.
• Mr. Chimovits is obligated to transfer any securities issued from these options, or their economic benefit, to OrbiMed Advisors LLC and related OrbiMed entities, which will then provide them to OrbiMed Private Investments VIII, LP and OrbiMed Israel Partners II, L.P.
• The filing was signed by Allison Ambrose as Attorney-in-Fact on June 12, 2025, under a substitute power of attorney.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a positive for aligning interests, but the transfer obligation to OrbiMed makes it less directly impactful for the individual director's personal wealth, which is a neutral structural aspect rather than a negative for the company itself. It's a routine filing.

Positives

• The grant of stock options to a director and 10% owner aligns their interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from a key stakeholder.

Negatives

• The obligation to transfer the economic benefit of the options to OrbiMed entities means the direct personal financial incentive for Mr. Chimovits from these specific options is limited, as the benefit flows to the funds he represents.

Risks

• The vesting of the options is subject to the reporting person's continued service, meaning the options could be forfeited if service ceases before vesting.
• Potential for perceived conflict of interest or reduced direct personal incentive for the director due to the obligation to transfer economic benefits to OrbiMed entities, although this is a common arrangement for representatives of institutional investors.

Future Outlook

The stock options granted to Director Erez Chimovits are subject to a vesting schedule, with shares vesting upon the earlier of June 10, 2026, or the date of the next Annual Meeting of Stockholders, contingent on his continued service. The options have an expiration date of June 9, 2035.

Management Comments

• The shares underlying this option shall vest upon the earlier of June 10, 2026, and the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
• Pursuant to an agreement with OrbiMed Advisors LLC and related entities, the Reporting Person is obligated to transfer any securities issued under such stock options or their economic benefit to these entities, which will in turn ensure such benefits are provided to OrbiMed Private Investments VIII, LP and OrbiMed Israel Partners II, L.P.

Industry Context

This Form 4 filing is a standard disclosure for insider transactions in publicly traded companies, common in the biotechnology or pharmaceutical sector where Upstream Bio operates. The grant of stock options is a typical form of equity compensation for directors, aiming to align their interests with shareholder value. The involvement of OrbiMed, a prominent healthcare investment firm, suggests that Mr. Chimovits' role is likely tied to his representation of OrbiMed's investment in Upstream Bio, which is a common structure for venture capital or private equity representatives on public company boards.

Comparison to Industry Standards

• The grant of stock options to directors is a common practice across industries, including biotech, to incentivize long-term commitment and performance, aligning director interests with shareholder value.
• The exercise price of $11.59 for the options is a specific value tied to the company's stock at the time of grant, which is standard for option grants.
• The vesting schedule (earlier of a specific date or next annual meeting, subject to continued service) is a typical mechanism for retaining board members and ensuring their ongoing contribution, comparable to practices at other biotech firms like Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors.
• The arrangement where the director is obligated to transfer the economic benefit to an investment fund (OrbiMed) is standard for directors who serve as representatives of institutional investors, ensuring the benefit accrues to the fund's limited partners rather than the individual director personally. This is seen in many portfolio companies of large investment firms.

Corporate Governance

Related Party Transactions

• Erez Chimovits, as a Director and 10% Owner, is obligated to transfer any securities issued under the granted stock options, or their economic benefit, to OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Israel GP II, L.P., and OrbiMed Advisors Israel II Limited. These entities will then ensure the benefits are provided to OrbiMed Private Investments VIII, LP and OrbiMed Israel Partners II, L.P. This indicates a transaction where the benefit flows to entities related to the director's primary affiliation (OrbiMed).

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholder value, although the ultimate economic benefit flows to OrbiMed funds. The transparency of the Form 4 filing provides insight into insider holdings.

Next Steps

• Vesting of the 17,096 stock options will occur upon the earlier of June 10, 2026, or the date of the next Annual Meeting of Stockholders, subject to continued service.
• Erez Chimovits is obligated to transfer the economic benefit of these options to OrbiMed entities.

Key Dates

Keywords

Upstream Bio, UPB, SEC Form 4, Stock Options, Erez Chimovits, Director, 10% Owner, OrbiMed, Beneficial Ownership, Equity Compensation, Insider Transaction, Vesting, Corporate Governance